CNSystems announces new CEO
This article was originally published in Clinica
CNSystems (Graz, Austria), which markets the CNAP a continuous, non invasive blood pressure management system, has appointed Paul Krell to the position of CEO. Mr Krell joins from Abiomed Europe (blood pumps for use in coronary surgery), where he was general manager for Europe. Prior to this he was vice-president for Europe at ev3's neurovascular division. He has more than 16 years' experience in the medical device industry, including nine years at Guidant in managerial roles, including as country manager for Germany (cardiac surgery products). Mr Krell succeeds Jürgen Fortin, the company's founder and CEO. Mr Fortin will continue as chief scientific officer and will focus on expanding the firm's technology portfolio and potential markets.
You may also be interested in...
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.